- |||||||||| AMG-228 / Amgen
Trial termination, Trial primary completion date, Metastases: Safety Study of AMG 228 to Treat Solid Tumors (clinicaltrials.gov) - Jan 13, 2017
P1, N=30, Terminated,
However, there was no evidence of T-cell activation or anti-tumor activity with AMG 228 monotherapy. Active, not recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Dec 2016
- |||||||||| AMG-228 / Amgen
Enrollment closed, Enrollment change, Metastases: Safety Study of AMG 228 to Treat Solid Tumors (clinicaltrials.gov) - Nov 10, 2016
P1, N=30, Active, not recruiting,
Active, not recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Dec 2016 Recruiting --> Active, not recruiting | N=100 --> 30
- |||||||||| AMG-228 / Amgen
Trial primary completion date, Metastases: Safety Study of AMG 228 to Treat Solid Tumors (clinicaltrials.gov) - Jun 5, 2016
P1, N=100, Recruiting,
Recruiting --> Active, not recruiting | N=100 --> 30 Trial primary completion date: Feb 2017 --> Oct 2017
|
